Stuart Feldman, DPM
Podiatrist · Henderson, NVNPI 1568685758
Payments from drug & device makers
What this record shows
This record is dominated by other: $30,345 of the $34,473 with a category attached, or 88.0%. Smith+Nephew accounts for 92.9% of it on its own, with 17 other manufacturers making up the rest. Reporting peaked in 2022 at $29,227 and has fallen 98.1% since, to $553 in 2025. Among podiatrist clinicians in NV with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 158 payments — averaging $218.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Smith+Nephew$32K
- Melinta Therapeutics, LLC$1K
- AbbVie$291
- Paratek Pharmaceuticals, Inc.$249
- Nevro Corp.$215
- Stryker$150
- plus $444 from 12 others
What the payments were for
- Food & beverage$4,12812%
- Other$30,34588%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Smith+Nephew | 50 | $32,018 |
| Melinta Therapeutics, LLC | 54 | $1,106 |
| AbbVie(2 entities) | 15 | $291 |
| Paratek Pharmaceuticals, Inc. | 12 | $249 |
| Nevro Corp. | 3 | $215 |
| Stryker | 1 | $150 |
| Novo Nordisk | 4 | $76 |
| Merck | 4 | $66 |
| Amgen | 3 | $47 |
| Boston Scientific | 1 | $40 |
| Kowa Pharmaceuticals America, Inc. | 2 | $39 |
| Orthofix Medical, Inc. | 3 | $38 |
| Organogenesis Inc. | 1 | $31 |
| Vertex | 1 | $28 |
| Medtronic | 1 | $24 |
| Hartmann USA, Inc. | 1 | $23 |
| Nalu Medical, Inc. | 1 | $18 |
| Cardiovascular Systems Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$34,473 in reported general payments places this provider in the 90th percentile of 44 podiatrist providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ammonium Lactate | 198 | $4,335 |
| Neomycin-Polymyxin-HcNeomycin/Polymyxin B/Hydrocort | 26 | $1,238 |
| Cephalexin | 29 | $620 |
| Diclofenac Sodium | 12 | $378 |
| Terbinafine Hcl | 44 | $305 |
| Naproxen | 26 | $241 |
| Prednisone | 40 | $135 |
Paid to pharmacies, not to this prescriber.
Other podiatrist in Henderson
- Blake SavageHenderson$18K
- Spencer NoordaHenderson$2K
- Anthony RicciardiLas Vegas$498K
- Jeremy AndersonLas Vegas$72K
- He XuLas Vegas$54K
- Peter BregmanLas Vegas$18K
- Anmy VuLas Vegas$15K
- Ai Quoc HellerLas Vegas$8K
- John CadeLas Vegas$6K
- Ada VeraLas Vegas$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.